Recent Quotes (30 days)

You have no recent quotes
chg | %

Transition Therapeutics Inc  

(Public, TSE:TTH)   Watch this stock  
Find more results for TTH
+0.06 (2.48%)
Nov 25 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 2.48 - 2.48
52 week 2.19 - 11.50
Open 2.48
Vol / Avg. 200.00/6,960.00
Mkt cap 96.42M
P/E     -
Div/yield     -
EPS -1.09
Shares 38.88M
Beta 0.89
Inst. own     -
Feb 8, 2016
Q2 2016 Transition Therapeutics Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 23, 2015
Transition Therapeutics Inc Investor Day
Nov 10, 2015
Q1 2016 Transition Therapeutics Inc Earnings Call
Nov 10, 2015
Q1 2016 Transition Therapeutics Inc Earnings Release
Sep 15, 2015
Q4 2015 Transition Therapeutics Inc Earnings Call
Sep 15, 2015
Q4 2015 Transition Therapeutics Inc Earnings Release

Key stats and ratios

Q3 (Sep '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -39.72% -86.61%
Return on average equity -51.92% -107.14%
Employees 18 -
CDP Score - -


101 College St Suite 220
+1-416-2607770 (Phone)
+1-416-2602886 (Fax)

Website links


Transition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes. The Company's subsidiary, Transition Therapeutics Ireland Limited (Transition Ireland), is developing two drug candidates: neuropsychiatric candidate ELND005 and androgen deficiency candidate TT701. The Company's subsidiary, Waratah Pharmaceuticals Inc. (Waratah), is developing diabetes drug candidate TT401. The Company's other two entities provide development services in support of the clinical and non-clinical activities of Transition Ireland and Waratah.

Officers and directors

Tony F. Cruz Ph.D. Chairman of the Board, Chief Executive Officer
Carl Damiani President, Chief Operating Officer
Age: 40
Nicole Rusaw Chief Financial Officer
Age: 39
Bruce Connop Vice President - Non-Clinical & Pharmaceutical Development
Age: 43
Aleksandra Pastrak Vice President - Clinical Development and Medical Officer
Age: 46
Louis Alexopoulos Secretary
Michael Richard Dwyer Ashton Lead Independent Director
Age: 69
Paul Baehr Independent Director
Age: 69
Christopher M. Henley Independent Director
Age: 52
Gary W. Pace Ph.D. Independent Director
Age: 67